Sanjiv Jayendra Shah

← Back to Northwestern University

ORCID

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

1. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

   2022 · 2,848 citations

2. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy

   2018 · 2,839 citations

3. Spironolactone for Heart Failure with Preserved Ejection Fraction

   2014 · 2,800 citations

4. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

   2019 · 2,421 citations

5. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity

   2023 · 1,633 citations

6. Phenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction

   2014 · 1,151 citations

7. Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial

   2014 · 1,065 citations

8. Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction

   2016 · 999 citations

9. Fully Automated Echocardiogram Interpretation in Clinical Practice

   2018 · 994 citations

10. SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials

    2022 · 985 citations

11. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

    2024 · 872 citations

12. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes

    2024 · 741 citations

13. Heart Failure With Preserved Ejection Fraction

    2023 · 720 citations

14. Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF

    2018 · 647 citations

15. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

    2021 · 616 citations

16. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial

    2011 · 578 citations

17. Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction

    2015 · 549 citations

18. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis

    2016 · 538 citations

19. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction

    2015 · 532 citations

20. The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF

    2018 · 498 citations

21. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation

    2009 · 493 citations

22. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2—evidence base and standardized methods of imaging

    2019 · 484 citations

23. Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone

    2015 · 478 citations

24. Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction

    2013 · 438 citations

25. Research Priorities for Heart Failure With Preserved Ejection Fraction

    2020 · 436 citations

← Return to the university profile